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Abstract
Introduction
Metaplastic breast carcinoma (MBC) is defined as breast cancer with a heterologous non-glandular
component. MBC is considered a special type of breast cancer with a prognosis that is worse than invasive
ductal carcinoma (IDC) of the breast. MBC is the most common breast cancer with a triple-negative profile.
Therefore, in this study, we evaluated the clinicopathological parameters, recurrence and survival of MBC in
our population.
Methods
We conducted a retrospective observational study in the Department of Histopathology at Prince
Faisal Oncology Centre, Buraidah, Saudi Arabia, over a period of five years. All cases diagnosed as MBC were
included in the study. Estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth
factor receptor 2 (HER2/neu) immunohistochemistry (IHC) was performed on representative tissue blocks.
Results
Total 183 cases of MBCs were included in the study, out of which 120 cases were excision specimens. The
mean age of the patients was 48.84±12.99 years, and the most common age group was between 36 and 50
years of age. Most of the cases were tumor (T) stage T3 (50%), and nodal metastasis was present in 40% of
cases. Most cases were grade III (78.7%). ER, PR and HER2/neu positivity was noted in 15.8%, 13.1%, and
9.8% cases, respectively. Follow-up data were available for 70 cases, with a median follow-up period of 4 (1-
7) years. Tumor recurrence was noted in 31.4% cases, with a survival rate of 71.4%. Squamous, chondroid,
spindle cell differentiation, and matrix production were noted in 70.5%, 7.1%, 13.7%, and 2.2% cases,
respectively. A significant association of squamous differentiation was noted with HER2/neu positivity. An
inverse association of spindle cell differentiation was seen with axillary metastasis. Survival analysis by
Kaplan-Meier revealed a significant association of survival with tumor recurrence.
Conclusion
MBC is an important subtype of breast cancer, histopathological identification of which is challenging,
owing to varied histological differentiation. We found squamous differentiation to be the most common in
MBC, which was associated with HER2/neu positivity. A high recurrence rate of MBC was also observed in
our study that was significantly associated with survival.
Categories: Pathology, General Surgery, Oncology
Keywords: metaplastic breast carcinoma, estrogen receptor, progesterone receptor, human epidermal growth factor
receptor 2, immunohistochemistry, breast cancer
Introduction
Metaplastic breast carcinoma (MBC) is defined as breast cancer with a heterologous non-glandular
component [1]. The heterologous component can be in the form of squamous metaplasia or
mesenchymal/sarcomatoid differentiation that resembles fibromatosis, fibrosarcoma, chondrosarcoma,
osteosarcoma, rhabdomyosarcoma, spindle cells, matrix-producing, and angiosarcoma or in combination.
MBC is considered a special type of breast cancer with a prognosis that is worse than invasive ductal
carcinoma (IDC) of the breast. Moreover, MBC is mostly negative for estrogen receptor (ER), progesterone
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receptor (PR), and human epidermal growth factor receptor 2 (HER2/neu), and therefore, the treatment
options are limited. In Pakistan, young-age breast cancers are common and the proportion of triple-negative
breast cancer is alarmingly high [2,3]. MBC is the most common breast cancer with a triple-negative profile
[4]. Therefore, in this study, we evaluated the clinicopathological parameters, recurrence, and survival of
MBC in our population.
Materials And Methods
We conducted a retrospective observational study in the Department of Histopathology at Prince
Faisal Oncology Centre, Buraidah, Saudi Arabia, over a period of five years. The specimens included were
trucut biopsy, lumpectomy and mastectomy with or without axillary lymph node dissection. Cases with
neoadjuvant chemotherapy before surgical excision were excluded from the study. The specimens were
received in the histopathology lab and were grossed according to standard protocols [5,6]. Representative
sections were taken from the tumor; resection margins and lymph nodes. Pathological parameters, such as
tumor size and grade, were recorded. All cases diagnosed as MBC in the study period were included in the
study. All slides and blocks were retrieved and histopathological diagnosis was reviewed by senior
pathologists. The diagnosis of MBC was suspected on histology based on features including squamous
differentiation, spindle cell (mesenchymal) differentiation, chondrosarcomatous/osteosarcomatous
differentiation or matrix production. Pancytokeratin and p63 immunostains were performed to confirm the
diagnosis of MBC (Figures 1A-1F, 2A-2F).
FIGURE 1: Metaplastic breast carcinoma with spindle cell
(mesenchymal) differentiation. (A) H & E-stained section at 40x
magnification showing sheets of spindle cell cells. (B) H & E-stained
section at 100x magnification revealing atypical spindled tumor cells.
(C) H & E-stained section of another area of tumor depicting epithelioid
tumor cells with a central area of necrosis (arrow). (D) 400x
magnification showing marked nuclear atypia with evident mitosis
(arrow). (E) Pan-cytokeratin immunostain showing patchy positivity in
the tumor (arrow). (F) p63 immunostaining revealing diffuse positivity in
tumor cells.
H & E, hematoxylin and eosin
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FIGURE 2: Metaplastic breast carcinoma, matrix-producing. (A) H & E-
stained section at 100x magnification showing clusters of tumor cells
with background matrix production. (B) H & E-stained section at 200x
magnification revealing tumor cells and clusters with matrix production
(arrow). (C) H & E-stained section at 400x magnification showing
moderate to marked atypia. (D) ER immunostaining showing negativity
in tumor cells. (E) PR immunostaining revealing absence of nuclear
expression in tumor cells. (F) HER2/neu immunostaining showing
absence of membranous positivity.
H & E, hematoxylin and eosin; ER, estrogen receptor; PR, progesterone receptor; HER2/neu, human
epidermal growth factor receptor 2
ER, PR and HER2/neu immunohistochemistry (IHC) was performed on representative tissue blocks. ER and
PR nuclear expression of more than 1% was considered positive. Strong and complete membranous
expression of HER2/neu in more than 10% tumor cells was taken as positive HER2/neu expression on IHC.
For cases with equivocal HER2/neu IHC, fluorescence in situ hybridization (FISH) studies were performed to
confirm the gene amplification, as performed in previous studies [7,8].
Data analysis was performed using Statistical Package for Social Sciences (Version 26.0, IBM Inc., Armonk,
USA). Chi-square, independent t-test, and Fisher’s exact tests were used to check the association. Survival
analysis was done by the Kaplan-Meier method. P-values < 0.05 were considered significant.
Results
Total 183 cases of MBCs were included in the study, out of which 120 cases were excision specimens. The
mean age of the patients was 48.84±12.99 years, and the most common age group was between 36 and 50
years of age. Most of the cases were tumor (T) stage T3 (50%), and nodal metastasis was present in 40% of
cases. Most cases were grade III (78.7%). ER, PR, and HER2/neu positivity was noted in 15.8%, 13.1%, and
9.8% cases, respectively. Follow-up data were available for 70 cases, with a median follow-up period of 4 (1-
7) years. Tumor recurrence was noted in 31.4% cases, with a survival rate of 71.4%. Squamous, chondroid,
spindle cell differentiation, and matrix production were noted in 70.5%, 7.1%, 13.7%, and 2.2% cases,
respectively (Table 1).
Clinicopathological characteristics Values
Age (years), mean±SD 48.84±12.99
Age groups  
≤35 years, n (%) 31 (16.9)
36-50 years, n (%) 81 (44.3)
>50 years, n (%) 71 (38.8)
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Tumor size (cm), mean±SD 5.85±3.14
Follow-up (years), median (range) 4 (1–7)
Laterality  
Right breast, n (%) 88 (48.1)
Left breast, n (%) 95 (51.9)
Specimen type  
Trucut biopsy, n (%) 63 (34.4)
Modified radical mastectomy (MRM), n (%) 48 (26.2)
Breast conservation surgery, n (%) 37 (20.2)
Simple mastectomy, n (%) 35 (19.1)
T-stage (n=120)  
T1, n (%) 10 (8.3)
T2, n (%) 50 (41.7)
T3, n (%) 60 (50)
Axillary metastasis  (n=120)  
Present, n (%) 48 (40)
Absent, n (%) 72 (60)
N-stage  (n=120)  
N0, n (%) 72 (60)
N1, n (%) 26 (21.7)
N2, n (%) 13 (10.8)
N3, n (%) 9 (7.5)
Grade  
Grade I, n (%) 1 (0.5)
Grade II, n (%) 38 (20.8)
Grade III, n (%) 144 (78.7)
ER  
Positive, n (%) 29 (15.8)
Negative, n (%) 154 (84.2)
PR  
Positive, n (%) 24 (13.1)
Negative, n (%) 159 (86.9)
HER2/neu  
Positive, n (%) 18 (9.8)
Negative, n (%) 165 (90.2)
Recurrence (n=70)  
Yes, n (%) 22 (31.4)
No, n (%) 48 (68.6)
Survival status (n=70)  
Alive, n (%) 50 (71.4)
2021 Haroon et al. Cureus 13(4): e14347. DOI 10.7759/cureus.14347 4 of 12
Expired, n (%) 20 (28.6)
Squamous differentiation  
Present, n (%) 129 (70.5)
Absent, n (%) 54 (29.5)
Chondroid differentiation  
Present, n (%) 13 (7.1)
Absent, n (%) 170 (92.9)
Spindle cell differentiation  
Present, n (%) 25 (13.7)
Absent, n (%) 158 (86.3)
Matrix production  
Present, n (%) 4 (2.2)
Absent, n (%) 179 (97.8)
TABLE 1: Descriptive statistics of study population
SD, standard deviation; T, tumor; N, nodal; ER, estrogen receptor; PR, progesterone receptor; HER2/neu, human epidermal growth factor receptor 2
Table 2 shows the association of squamous differentiation with clinicopathological and prognostic
parameters. A significant association of squamous differentiation was noted with HER2/neu positivity.





Age (years)*, mean±SD 48.84±10.83 48.84±13.32 0.999
Age groups**    
≤35 years, n (%) 22 (17.1) 9 (16.7)
0.55936-50 years, n (%) 54 (41.9) 27 (50)
>50 years, n (%) 53 (41.1) 18 (33.3)
Tumor size (cm)*, mean±SD 5.93±2.67  5.83±3.21 0.913
T-stage (n=120)**    
T1, n (%) 9 (11.7) 1 (2.3)
0.163T2, n (%) 29 (37.7) 21 (48.8)
T3, n (%) 39 (50.6) 21 (48.8)
Axillary metastasis  (n=120)**    
Present, n (%) 31 (40.3) 17 (39.5)
0.938
Absent, n (%) 46 (59.7) 26 (60.5)
N-stage  (n=120)***    
N0, n (%) 46 (59.7) 26 (60.5)
0.314
N1, n (%) 14 (18.2) 12 (27.9)
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N2, n (%) 9 (11.7) 4 (9.3)
N3, n (%) 8 (10.4) 1 (2.3)
Grade**    
Grade I, n (%) 1 (0.8) 0 (0)
0.520Grade II, n (%) 24 (18.6) 14 (25.9)
Grade III, n (%) 104 (80.6) 40 (74.1)
ER**    
Positive, n (%) 20 (15.5) 9 (16.7)
0.844
Negative, n (%) 109 (84.5) 45 (83.3)
PR**    
Positive, n (%) 19 (14.7) 5 (9.3)
0.317
Negative, n (%) 110 (85.3) 49 (90.7)
HER2/neu**    
Positive, n (%) 18 (14) 0 (0)
0.004****
Negative, n (%) 111 (86) 54 (100)
Recurrence (n=70)***    
Yes, n (%) 18 (37.5) 4 (18.2)
0.165
No, n (%) 30 (62.5) 18 (81.8)
Survival status (n=70)***    
Alive, n (%) 32 (66.7) 18 (81.8)
0.259
Expired, n (%) 16 (33.3) 4 (18.2)
TABLE 2: Association of squamous differentiation with clinicopathological features
*Independent t-test was applied, **Chi-square test was applied, ***Fisher’s exact test was applied, ****p-value significant as <0.05
SD, standard deviation; T, tumor; N, nodal; ER, estrogen receptor; PR, progesterone receptor; HER2/neu, human epidermal growth factor receptor 2
Table 3 depicts the association of chondroid differentiation with pathological and prognostic factors;






Age (years)*, mean±SD 46.53±11.97 49.01±13.08 0.509
Age groups**    
≤35 years, n (%) 3 (23.1) 28 (16.5)
0.43536-50 years, n (%) 7 (53.8) 74 (43.5)
>50 years, n (%) 3 (23.1) 68 (40)
Tumor size (cm)*, mean±SD 6.51±3.58 5.79±3.10 0.490
T-stage (n=120)**    
T1, n (%) 0 (0) 10 (9.1)
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0.519T2, n (%) 6 (60) 44 (40)
T3, n (%) 4 (40) 56 (50.9)
Axillary metastasis (n=120)**    
Present, n (%) 3 (30) 45 (40.9)
0.738
Absent, n (%) 7 (70) 65 (59.1)
N-stage  (n=120)**    
N0, n (%) 7 (7) 65 (59.1)
1.000
N1, n (%) 2 (20) 24 (21.8)
N2, n (%) 1 (10) 12 (10.9)
N3, n (%) 0 (0) 9 (8.2)
Grade**    
Grade I, n (%) 0 (0) 1 (0.6)
0.100Grade II, n (%) 6 (46.2) 32 (18.8)
Grade III, n (%) 7 (53.8) 137 (80.6)
ER**    
Positive, n (%) 2 (15.4) 27 (15.9)
1.000
Negative, n (%) 11 (84.6) 143 (84.1)
PR**    
Positive, n (%) 2 (15.4) 22 (12.9)
0.681
Negative, n (%) 11 (84.6) 148 (87.1)
HER2/neu**    
Positive, n (%) 0 (0) 18 (10.6)
0.370
Negative, n (%) 13 (100) 152 (89.4)
Recurrence (n=70)**    
Yes, n (%) 2 (50) 20 (30.3)
0.585
No, n (%) 2 (50) 46 (69.7)
Survival status (n=70)**    
Alive, n (%) 4 (100) 46 (69.7)
0.318
Expired, n (%) 0 (0) 20 (30.3)
TABLE 3: Association of chondroid differentiation with clinicopathological features
*Independent t-test was applied, **Fisher’s exact test was applied
SD, standard deviation; T, tumor; N, nodal; ER, estrogen receptor; PR, progesterone receptor; HER2/neu, human epidermal growth factor receptor
An inverse association of spindle cell differentiation was seen with axillary metastasis. Cases of MBC with
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Yes No
Age (years)*, mean±SD 48.84±10.83 48.84±13.32 0.999
Age groups***    
≤35 years, n (%) 2 (8) 29 (18.4)
0.34436-50 years, n (%) 14 (56) 67 (42.4)
>50 years, n (%) 9 (36) 62 (39.2)
Tumor size (cm)*, mean±SD 5.93±2.67 5.83±3.21 0.913
T-stage (n=120)***    
T1, n (%) 1 (6.7) 9 (8.6)
0.833T2, n (%) 5 (33.3) 45 (42.9)
T3, n (%) 9 (60) 51 (48.6)
Axillary metastasis (n=120)**    
Present, n (%) 2 (13.3) 46 (43.8)
0.024****
Absent, n (%) 13 (86.7) 59 (56.2)
N-stage  (n=120)***    
N0, n (%) 13 (86.7) 59 (56.2)
0.174
N1, n (%) 2 (13.3) 24 (22.9)
N2, n (%) 0 (0) 13 (12.4)
N3, n (%) 0 (0) 9 (8.6)
Grade***    
Grade I, n (%) 0 (0) 1 (0.6)
0.161Grade II, n (%) 9 (36) 29 (18.4)
Grade III, n (%) 16 (64) 128 (81)
ER***    
Positive, n (%) 2 (8) 27 (17.1)
0.378
Negative, n (%) 23 (92) 131 (82.9)
PR***    
Positive, n (%) 0 (0) 24 (15.2)
0.049****
Negative, n (%) 25 (100) 134 (84.8)
HER2/neu***    
Positive, n (%) 0 (0) 18 (11.4)
0.139
Negative, n (%) 25 (100) 140 (88.6)
Recurrence (n=70)***    
Yes, n (%) 2 (25) 20 (32.3)
1.000
No, n (%) 6 (75) 42 (67.7)
Survival status (n=70)***    
Alive, n (%) 4 (50) 46 (74.2)
0.212
Expired, n (%) 4 (50) 16 (25.8)
TABLE 4: Association of spindle cell differentiation with clinicopathological features
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*Independent t-test was applied, **Chi-square test was applied, ***Fisher’s exact test was applied, ****p-value significant as <0.05
SD, standard deviation; T, tumor; N, nodal; ER, estrogen receptor; PR, progesterone receptor; HER2/neu, human epidermal growth factor receptor
Table 5 shows the association of matrix-producing MBC with prognostic and pathological parameters,





Age (years)*, mean±SD 43.75±5.31 48.95±13.09 0.430
Age groups**    
≤35 years, n (%) 0 (0) 31 (17.3)
0.13336-50 years, n (%) 4 (100) 77 (43)
>50 years, n (%) 0 (0) 71 (39.7)
Tumor size (cm)*, mean±SD 6.65±4.91 5.82±3.09 0.606
T-stage (n=120)**    
T1, n (%) 0 (0) 10 (8.6)
0.528T2, n (%) 3 (75) 47 (40.5)
T3, n (%) 1 (25) 59 (50.9)
Axillary metastasis (n=120)**    
Present, n (%) 2 (50) 46 (39.7)
1.000
Absent, n (%) 2 (50) 70 (60.3)
N-stage  (n=120)**    
N0, n (%) 2 (50) 70 (60.3)
0.581
N1, n (%) 2 (50) 24 (20.7)
N2, n (%) 0 (0) 13 (11.2)
N3, n (%) 0 (0) 9 (7.8)
Grade**    
Grade I, n (%) 0 (0) 1 (0.6)
1.000Grade II, n (%) 1 (25) 37 (20.7)
Grade III, n (%) 3 (75) 141 (78.8)
ER**    
Positive, n (%) 2 (50) 27 (15.1)
0.119
Negative, n (%) 2 (50) 152 (84.9)
PR**    
Positive, n (%) 2 (50) 22 (12.3)
0.084
Negative, n (%) 2 (50) 157 (87.7)
HER2/neu**    
Positive, n (%) 0 (0) 18 (10.1)
1.000
Negative, n (%) 4 (100) 161 (89.9)
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Recurrence (n=70)**    
Yes, n (%) 0 (0) 22 (32.4)
1.000
No, n (%) 2 (100) 46 (67.6)
Survival status (n=70)**    
Alive, n (%) 2 (100) 48 (70.6)
1.000
Expired, n (%) 0 (0) 20 (29.4)
TABLE 5: Association of matrix production with clinicopathological features
*Independent t-test was applied, **Fisher’s exact test was applied
SD, standard deviation; T, tumor; N, nodal; ER, estrogen receptor; PR, progesterone receptor; HER2/neu, human epidermal growth factor receptor
Survival analysis by Kaplan-Meier revealed a significant association of survival with tumor recurrence.
Patients of MBC with recurrence had lower survival than cases without tumor recurrence (Figure 3).
FIGURE 3: Association of tumor recurrence with survival
Discussion
MBC is an aggressive breast cancer type that accounts for approximately one percent of invasive breast
cancer [9]. The neoplastic epithelium tends to differentiate into various heterologous non-glandular
components such as metaplastic squamous cells and mesenchymal elements with sarcomatoid, rhabdoid,
spindle, or other morphological patterns [9]. MBCs are usually larger in size at the time of diagnosis
compared with IDC and other breast cancer subtypes and typically have a poor prognosis [9,10]. MBCs lack
hormone receptors (ER, PR) and HER2/neu expression and are therefore difficult to treat [3,4,9,10]. MBCs
have almost two times higher rates of recurrence than other triple-negative breast cancers and a shorter
overall disease-free survival [11]. Previous literature has mentioned that MBC responds poorly to various
chemotherapeutic regimens [10,11].
Nowara et al. found that adjuvant radiation therapy (in addition to standard chemotherapy) was associated
with significantly improved survival and recommended further studies on a larger group [12]. Beatty et al.
found that even though MBCs had overall worse prognostic features, aggressive multidisciplinary
management was associated with comparable outcomes between MBC and conventional breast cancer cases
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[13]. Pezzi et al. reported that MBCs tend to involve axillary lymph nodes less commonly but metastasize to
distant locations more frequently [14]. Chen et al. reported poor response to several chemotherapeutic
agents with a relatively better response to taxane-based chemotherapy [15]. McCart Reed et al. reported that
loss of cytokeratin expression, overexpression of epidermal growth factor receptor (EGFR) and the
coexistence of multiple morphological patterns were associated with poor prognosis in addition to the
previously described prognostic factors such as tumor size and grade [16]. Cimino-Mathews et al. compared
multiple studies and further reported an overall poor prognosis of MBC despite aggressive therapy and
stated that MBCs express high levels of vascular/angiogenesis markers like vascular endothelial growth
factor and suggested targeted therapy trials in future studies [17].
MBCs are a heterogeneous group of tumors including both low-grade and prognostically better tumors,
along with high-grade and prognostically poor tumors. The biological behavior of these tumors correlates
with tumor grade. The low-grade adenosquamous and fibromatosis-like carcinomas are associated with
indolent clinical behavior [18]. Alternatively, high-grade adenosquamous carcinoma and high-grade spindle
cell carcinomas are associated with a poor prognosis [19]. Matrix-producing MBCs are also associated with a
relatively better prognosis than other high-grade subtypes of MBC [19]. We also noted that the matrix
production was inversely associated with axillary metastasis.
In our study, mean tumor size was 5.85±3.14 cm. Previous studies have emphasized that MBC tends to have
larger tumor size (higher T-stage), and a lower incidence of axillary metastasis (lower N-stage) than IDC [20].
As MBCs tend to present at a higher T-stage, a significant subset of patients require neoadjuvant
chemotherapy. However, MBCs are associated with a poor response to neoadjuvant chemotherapy with a
complete pathological response rate of 10%-17% [21].
The main differential diagnosis of spindle cell MBC is malignant phyllodes tumor (MPT). However, MPT
typically has a leaf-like architecture with benign slit-like entrapped epithelial elements. In difficult cases,
immunohistochemistry with pancytokeratin, p63, and CD34 is helpful. While MBCs are positive (at least
focally) with pancytokeratin and p63, MPTs show positive expression with CD34.
Our study had few limitations, including small sample size and single-institution data, but showed overall
comparable results with significant association of squamous differentiation with HER2/neu expression and
recurrence with survival. More clinical trials are required with targeted therapies to determine treatment
response and survival improvement.
Conclusions
MBC is an aggressive subtype of breast cancer and its histopathological identification is essential as it
displays unique clinicopathological characteristics, including the lack of expression of hormone receptors
and HER2/neu. We noted that squamous differentiation is the most common histological pattern, and
squamous differentiation was significantly associated with HER2/neu positivity in MBC in our study.
Moreover, spindle cell differentiation was inversely associated with axillary metastasis. A high frequency of
tumor recurrence was noted in our study in patients with MBC, and recurrence was also noted to be
significantly associated with the patient’s survival.
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